Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial

PITCH Consortium, Matthew W. Jenner, Roger G Owen, Dickens Pratt, Gordon Cook, Alex Richter, Mark Drayson, Martin F Kaiser

Research output: Contribution to journalArticlepeer-review

33 Downloads (Pure)

Abstract

Multiple myeloma (MM) and anti-MM therapy cause profound immunosuppression, leaving patients vulnerable to coronavirus disease 2019 (COVID-19) and other infections. We investigated anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies longitudinally in ultra-high-risk patients with MM receiving risk-adapted, intensive anti-CD38 combined therapy in the Myeloma UK (MUK) nine trial. Despite continuous intensive therapy, seroconversion was achieved in all patients, but required a greater number of vaccinations compared to healthy individuals, highlighting the importance of booster vaccinations in this population. Reassuringly, high antibody cross-reactivity was found with current variants of concern, prior to Omicron subvariant adapted boostering. Multiple booster vaccine doses can provide effective protection from COVID-19, even with intensive anti-CD38 therapy for high-risk MM.
Original languageEnglish
Pages (from-to)845-850
JournalBritish Journal of Haematology
Volume201
Issue number5
Early online date9 Mar 2023
DOIs
Publication statusPublished - 21 May 2023

Keywords

  • antibodies
  • anti-CD38
  • high-dose therapy
  • multiple myeloma
  • severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
  • SHORT REPORT
  • severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)
  • anti‐CD38
  • SHORT REPORTS
  • high‐dose therapy

Fingerprint

Dive into the research topics of 'Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial'. Together they form a unique fingerprint.

Cite this